Toll-like Receptor 3 (D10F10) Rabbit Monoclonal Antibody#6961,Cell Signaling Technology (CST),6961

Members of the Toll-like receptor (TLR) family, named for the closely related Toll receptor inDrosophila, play a pivotal role in innate immune responses (1-4). TLRs recognize conserved motifs found in various pathogens and mediate defense responses (5-7). Triggering of the TLR pathway leads to the activation of NF-κB and subsequent regulation of immune and inflammatory genes (4). The TLRs and members of the IL-1 receptor family share a conserved stretch of approximately 200 amino acids known as the Toll/Interleukin-1 receptor (TIR) domain (1). Upon activation, TLRs associate with a number of cytoplasmic adapter proteins containing TIR domains, including myeloid differentiation factor 88 (MyD88), MyD88-adapter-like/TIR-associated protein (MAL/TIRAP), TIR domain-containing adapter-inducing IFN-β (TRIF), and Toll-receptor-associated molecule (TRAM) (8-10). This association leads to the recruitment and activation of IRAK1 and IRAK4, which form a complex with TRAF6 to activate TAK1 and IKK (8,11-14). Activation of IKK leads to the degradation of IκB, which normally maintains NF-κB in an inactive state by sequestering it in the cytoplasm.TLR3 functions as a receptor for double-stranded (ds)RNA typically associated with viral infection (4). It was originally shown to be specifically expressed in dendritic cells of the leukocyte family (5). TLR3 has also been found in placenta and lung, and can be induced by LPS in a variety of tissues (4,6). TLR3 is predominantly localized to early endosomes (7,8). Binding of dsRNA, or the analog polyinosine-polycytidylic acid (pIpC), to TLR3 triggers activation of transcription factors NF-κB and IRF3 through the adaptor protein TICAM-1/TRIF (9,10). TRIF associates with members of the TRAF family and with RIP that combine to activate NF-κB and IRF3 (11-13).Akira, S. (2003)J Biol Chem278, 38105-8.Beutler, B. (2004)Nature430, 257-63.Dunne, A. and O'Neill, L.A. (2003)Sci STKE2003, re3.Medzhitov, R. et al. (1997)Nature388, 394-7.Schwandner, R. et al. (1999)J Biol Chem274, 17406-9.Takeuchi, O. et al. (1999)Immunity11, 443-51.Alexopoulou, L. et al. (2001)Nature413, 732-8.Zhang, F.X. et al. (1999)J Biol Chem274, 7611-4.Horng, T. et al. (2001)Nat Immunol2, 835-41.Oshiumi, H. et al. (2003)Nat Immunol4, 161-7.Muzio, M. et al. (1997)Science278, 1612-5.Wesche, H. et al. (1997)Immunity7, 837-47.Suzuki, N. et al. (2002)Nature416, 750-6.Irie, T. et al. (2000)FEBS Lett467, 160-4.Alexopoulou, L. et al. (2001)Nature413, 732-8.Muzio, M. et al. (2000)J Immunol164, 5998-6004.Nishimura, M. and Naito, S. (2005)Biol Pharm Bull28, 886-92.Matsumoto, M. et al. (2003)J Immunol171, 3154-62.Funami, K. et al. (2007)J Immunol179, 6867-72.Hoebe, K. et al. (2003)Nat Immunol4, 1223-9.Oshiumi, H. et al. (2003)Nat Immunol4, 161-7.Sasai, M. et al. (2010)Mol Immunol47, 1283-91.Meylan, E. et al. (2004)Nat Immunol5, 503-7.Jiang, Z. et al. (2004)Proc Natl Acad Sci USA101, 3533-8.Alternate NamesCD283; IIAE2; TLR3; toll like receptor 3; Toll-like receptor 3

CD283; IIAE2; TLR3; toll like receptor 3; Toll-like receptor 3